Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone
Sleep D, Nelson J, Petrylak D, Isaacson J, Carducci M. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. Journal Of Clinical Oncology 2006, 24: 4630-4630. DOI: 10.1200/jco.2006.24.18_suppl.4630.Peer-Reviewed Original ResearchHormone-refractory prostate cancerDisease progressionHRPC patientsBone metastasesProstate cancer metastaticKaplan-Meier methodDelays disease progressionEffects of endothelinDisease progression eventsCox proportional hazardsProgression of morbidityBone painCancer metastaticRadiographic progressionProlong survivalClinical benefitClinical progressionSelective endothelinClinical eventsReceptor antagonistMultinational trialProstate cancerClinical meansAtrasentanNew therapies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply